American Heart Journal
Volume 156, Issue 1 , Pages 23-30 , July 2008

Challenges in meta-analysis of randomized clinical trials for rare harmful cardiovascular events: The case of rosiglitazone

  • Adrian V. Hernandez, MD, MSc, PhD

      Affiliations

    • Department of Quantitative Health Sciences, Health Outcomes and Clinical Epidemiology Section, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH
    • Corresponding Author InformationReprint requests: Adrian V. Hernandez, MD, MSc, PhD, Department of Quantitative Health Sciences/Wb4, Lerner Research Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195.
    • ,
  • Esteban Walker, PhD

      Affiliations

    • Department of Quantitative Health Sciences, Biostatistics Section, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH
    • ,
  • John P.A. Ioannidis, MD, PhD

      Affiliations

    • Department of Hygiene and Epidemiology, Clinical Trials and Evidence-Based Medicine Unit, University of Ioannina School of Medicine, Ioannina, Greece
    • Department of Medicine, Institute for Clinical Research and Health Policy Studies, Tufts-New England Medical Center, Boston, MA
    • ,
  • Michael W. Kattan, PhD

      Affiliations

    • Department of Quantitative Health Sciences, Health Outcomes and Clinical Epidemiology Section, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH

Received 7 January 2008 ,Accepted 4 March 2008.

References 

  1. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457–2471
  2. Psaty BM, Furberg CD. Rosiglitazone and cardiovascular risk. N Engl J Med. 2000;356:2522–2524
  3. The Lancet . Rosiglitazone: seeking a balanced perspective. Lancet. 2007;[published online May 23]
  4. Home PD, Pocock SJ, Beck-Nielsen H, et al. for the RECORD Study Group Rosiglitazone evaluated for cardiovascular outcomes—an interim analysis. N Engl J Med. 2007;357:28–38
  5. Nathan DM. Rosiglitazone and cardiotoxicity—weighing the evidence. N Engl J Med. 2007;357:64–66
  6. Psaty BM, Furberg CD. The record of rosiglitazone and the risk of myocardial infarction. N Engl J Med. 2007;357:67–69
  7. Krall RL. Cardiovascular safety of rosiglitazone. Lancet. 2007;369:1995–1996
  8. Fuster V, Farkouh ME. Faster publication isn't always better. Nat Clin Pract Cardiovasc Med. 2007;4:345
  9. GlaxoSmithKline . Study no. ZM2005/00181/01; Avandia Cardiovascular Event Modeling Project. Available at: http://ctr.gsk.co.uk/Summary/Rosiglitazone/III_CVmodeling.pdf)Accessed October 2, 2007
  10. Diamond GA, Bax L, Kaul S. Uncertain effects of rosiglitazone on the risk of myocardial infarction and cardiovascular death. Ann Intern Med. 2007;147:578–581
  11. Bracken MB. Rosiglitazone and cardiovascular risk. N Engl J Med. 2007;357:937–938
  12. Shuster JJ, Jones LS, Salmon DA. Fixed vs. random effects meta-analysis in rare event studies: the rosiglitazone link with myocardial infarction and cardiac death. Stat Med. 2007;26:4375–4385
  13. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone. A meta-analysis. JAMA. 2007;298:1189–1195
  14. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis if randomized clinical trials. Lancet. 2007;370:1129–1136
  15. Ross SD, Kuperlnick B, Kumashiro M, et al. Risk of serious adverse events in hypertensive patients receiving isradipine: a meta-analysis. J Hum Hypertens. 1997;11:743–751
  16. Konstam MA, Weir MR, Reicin A, et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation. 2001;104:2280–2288
  17. Jüni P, Narty L, Reichenbach S, et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet. 2004;364:2021–2029
  18. Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of β-agonists in patients with asthma and COPD—a meta-analysis. Chest. 2004;125:2309–2321
  19. Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006;332:1302–1308
  20. Caldwell B, Aldington S, Weatherall M, et al. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med. 2006;99:132–140
  21. White B, West CR, Borer JS, et al. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized controlled trials. Am J Cardiol. 2007;99:91–98
  22. Chen LC, Ashcroft DM. Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials. Pharmacoepidemiol Drug Saf. 2007;16:762–772
  23. In:  Higgins JPT,  Green S editor. Cochrane handbook for systematic reviews of interventions 4.2.6 [updated September 2006]. The Cochrane Library, Issue 4. Chichester, UK: John Wiley & Sons, Ltd; 2006;p. 126–146
  24. Bradburn MJ, Deeks JJ, Berlin JA, et al. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med. 2007;26:53–77
  25. Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Med. 1985;27:335–371
  26. McQuay HJ, Moore RA. Using numerical results for systematic reviews in clinical practice. Ann Intern Med. 1997;126:720–721
  27. Deeks JJ. Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes. Stat Med. 2002;21:1575–1600
  28. Papanikolaou PN, Christidi GD, Ioannidis JP. Comparison of evidence on harms of medical interventions in randomized and nonrandomized studies. CMAJ. 2006;174:635–641
  29. Hernandez AV, Westerhout CM, Steyerberg EW, et al. Effects of platelet glycoprotein IIb/IIIa receptor blockers in non-ST segment elevation acute coronary syndromes: benefit and harm in different age subgroups. Heart. 2007;93:450–455
  30. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427–2443[Erratum, N Engl J Med 2007;356:1387-8.]
  31. Gerstein HC, Yusuf S, Bosch J, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet. 2006;368:1096–1105[Erratum, Lancet 2006;368:1770]
  32. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med. 2004;23:1351–1375
  33. Nissen SE, Wolski K. Rosiglitazone and cardiovascular risk. N Engl J Med. 2007;357:939–940
  34. Ioannidis JP, Chew P, Lau J. Standardized retrieval of side effects data for meta-analysis of safety outcomes. J Clin Epidemiol. 2002;55:619–626
  35. Lau J, Ioannidis JP, Schmid CH. Summing up evidence: one answer is not always enough. Lancet. 1998;351:123–127
  36. Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2:e124
  37. Early Breast Cancer Trialists' Collaborative Group. In: Treatment of early breast cancer. Worldwide evidence 1985-1990. Vol. 1:Oxford: Oxford University Press; 1990;p. 12–18
  38. Hauben M, Reich L, Van Puijenbroek EP, et al. Data mining in pharmacovigilance: lessons from phantom ships. Eur J Clin Pharmacol. 2006;62:967–970
  39. Jorgensen AW, Hilden J, Gotzsche PC. Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review. BMJ. 2006;333:782
  40. Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA. 2001;285:437–443
  41. Papanikolaou PN, Ioannidis JP. Availability of large-scale evidence on specific harms from systematic reviews of randomized trials. Am J Med. 2004;117:582–589
  42. Ioannidis JP, Evans SJ, Gotzsche PC, et al. CONSORT Group Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med. 2004;141:781–788

PII: S0002-8703(08)00162-2

doi: 10.1016/j.ahj.2008.03.002

American Heart Journal
Volume 156, Issue 1 , Pages 23-30 , July 2008

Article Tools

* Image Usage & Resolution